RNS & Investor News

Grant of Options

27 March 2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Frederic Narbel, a newly appointed Director of the Company, at an exercise price of 78.5p. Full details of the options agreement are set out below.

Director Number of options Exercise price
Frederic Narbel 500,000 78.5p

The options were granted with an effective date of 25 March 2019 and may be exercised up to 10 years from this date.

The options have performance criteria attached to them which includes significant revenue targets. Option holders can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract and retain key staff who deliver to revenue targets and build shareholder value is important to OptiBiotix's continued success. The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the team to focus both effort and activity on rapidly growing revenues and building shareholder value. These options are offered to staff and do not become exercisable (i.e. sellable) until they achieve significant revenue targets which, if achieved, will create substantive shareholder value".

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Frederic Narbel
2 Reason for notification
a. Position/Status Managing Director of Prebiotics, Director of the Company
b. Initial notification/ Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name OptiBiotix Health Plc
b. LEI 213800UKYQFT941QHS14
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code
Options over 500,000 ordinary shares of 2p each with an exercise price of 78.5p
ISIN: GB00BP0RTP38
b. Nature of the transaction Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Frederic Narbel has an interest in options over 500,000 ordinary shares.
c. Price(s) and volume(s)      
  Price(s) per share Volume(s)  
78.5p 500,000  
 
d. Date of the transaction 27 March 2019
e. Place of the transaction London Stock Exchange, AIM